Abstract
The present clinical trial update consists of a review of two of eight current studies (the 10981-22023 AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is designed to prove equivalent local/regional control for patients with proven axillary lymph node metastasis by sentinel node biopsy if treated with axillary radiotherapy instead of axillary lymph node dissection, with reduced morbidity. The p53 trial started to assess the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane regimen versus a nontaxane regimen. © 2004 BioMed Central Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 165-169 |
| Number of pages | 5 |
| Journal | Breast cancer research |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adjuvant chemotherapy
- Breast neoplasm(s)
- Clinical trials
- P53
- Sentinel node biopsy
Fingerprint
Dive into the research topics of 'Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver